Skip to main content

Table 1 Assessment of comorbidities in the outcomes of HIV–AIDS inpatients

From: Immunologic biomarkers, morbidity and mortality among HIV patients hospitalised in a Tertiary Care Hospital in the Brazilian Amazon

Clinical data Death Discharge p
N = 17 N = 66
Age (mean, std.) 37.6 (9.9) 36.2 (9.4) 0.590
Gender (male) 11 (64.7) 54 (81.8) 0.184
ART 12 (70.6) 55 (83.3) 0.300
CD4 T < 350 cells/mL 14 (82.4) 58 (87.9) 0.688
HIV-RNA > 1000 copies 14 (82.4) 47 (71.2) 0.539
Weight loss 14 (82.4) 30 (45.5) 0.007**
Very good condition 7 (41.2) 35 (53.0) 0.425
Lucid and space-oriented 8 (47.1) 40 (60.6) 0.410
Anemia 15 (88.2) 43 (65.2) 0.079
Respiratory disorder 14 (82.4) 42 (63.6) 0.244
Neurological disorder 8 (47.1) 29 (43.9) 0.999
Cardiovascular disorder 2 (11.8) 2 (3.0) 0.184
Gastrointestinal disorder 8 (47.1) 16 (24.2) 0.077
Active coinfections
 Tuberculosis 12 (70.6) 25 (37.9) 0.026*
 Parasites in stools 3 (17.6) 13 (19.7) 0.999
 Toxoplasmosis IgM 1 (5.9) 7 (10.6) 0.999
 Cytomegalovirus IgM 1 (5.9) 2 (3.0) 0.502
 Epstein Barr virus IgM 17 (100) 66 (100) 0.999
 Herpes virus IgM 0 (0) 3 (4.5) 0.999
Previous infections
 HCV IgG 1 (5.9) 2 (3.0) 0.502
 Cytomegalovirus IgG 13 (76.5) 53 (80.3) 0.741
 Toxoplasmosis IgG 13 (76.5) 52 (78.8) 0.999
 Epstein Barr virus IgG 12 (70.6) 49 (74.2) 0.764
 Herpes virus IgG 12 (70.6) 44 (66.7) 0.999
  1. *, **: p-value; statistically significant difference